Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February 2010
GSK and XNPT today announced that FDA has extended the original PDUFA goal date for its review of NDA for GSK to February 9, 2010.
-
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine
First prequalification for pneumococcal disease vaccine, a threatening disease affecting many children; follows first World Pneumonia Day.
-
World’s largest malaria vaccine trial now underway in seven African countries
Pivotal testing of RTS,S is on track for target enrollment of 16,000 children
-
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
CEO promises 'relentless pursuit' of new treatments
-
Retigabine Regulatory Update
on 30 October, they filed a New Drug Application with the FDA and MAA with EMEA for retigabine.
-
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
Benlysta 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement.
-
Results announcement for the third quarter 2009
See the quarterly results page for more information.
-
Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population
GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine.
-
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the first patient has commenced treatment.
-
GSK and Genmab receive accelerated approval for Arzerra™
Today, GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the accelerated approval of Arzerra TM (ofatumumab).
-
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
GSK today announced that, to date, more than 150,000 people have received GSK pandemic H1N1 vaccine, Pandemrix.
-
GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus
Benlysta (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; delayed time-to-first SLE disease flare.
-
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
GSK announced that FDA has approved Votrient to treat patients with advanced renal cell carcinoma (RCC).
-
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
GSK announced today that FDA has approved Cervarix[Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant].
-
Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability
GSK announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine.
-
GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan
Landmark approval paves the way for access to the vaccine for women in Japan
-
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
GlaxoSmithKline plc (GSK) announced today that it has entered into a unique partnership with the UK Government.
-
GSK partners with UK Government and Wellcome Trust to stimulate innovation through the creation of a world-class science park
GSK announced today the U.S. Food and Drug Administration (FDA) has not yet completed the review of the Biologics License Application.
-
GSK’s Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
GSK announced today that it has filed a sNDA for Avodart with the FDA for prostate cancer among men at increased of developing the disease.
-
GlaxoSmithKline and U.S. Patent and Trademark Office file a motion to dismiss litigation over Final Regulations
GSK and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics.
